JP2013530999A - sn−2−モノアシルグリセロール及び脂質吸収不良 - Google Patents
sn−2−モノアシルグリセロール及び脂質吸収不良 Download PDFInfo
- Publication number
- JP2013530999A JP2013530999A JP2013517348A JP2013517348A JP2013530999A JP 2013530999 A JP2013530999 A JP 2013530999A JP 2013517348 A JP2013517348 A JP 2013517348A JP 2013517348 A JP2013517348 A JP 2013517348A JP 2013530999 A JP2013530999 A JP 2013530999A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition according
- composition
- lipid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 40
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 39
- 229930195729 fatty acid Natural products 0.000 claims abstract description 39
- 239000000194 fatty acid Substances 0.000 claims abstract description 39
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 33
- 125000006239 protecting group Chemical group 0.000 claims abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 11
- 125000002252 acyl group Chemical group 0.000 claims abstract description 6
- 125000005313 fatty acid group Chemical group 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 8
- 206010025476 Malabsorption Diseases 0.000 claims description 7
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 5
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
- JDKIKEYFSJUYJZ-OUJQXAOTSA-N (5Z,11Z,14Z,17Z)-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCC\C=C/CCCC(O)=O JDKIKEYFSJUYJZ-OUJQXAOTSA-N 0.000 claims description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 3
- HOEFYOYIBRBTLY-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)docosa-4,6,8,10,12-pentaen-3-one Chemical compound C(C=CC=CC=CC=CC=CCCCCCCCCC)(=O)C(CO)(O)CO HOEFYOYIBRBTLY-UHFFFAOYSA-N 0.000 claims description 3
- RZTFXZWNZOLGOH-UHFFFAOYSA-N 1,3-diacetyloxypropan-2-yl icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC(COC(C)=O)COC(C)=O RZTFXZWNZOLGOH-UHFFFAOYSA-N 0.000 claims description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 3
- 206010021036 Hyponatraemia Diseases 0.000 claims description 3
- 239000003833 bile salt Substances 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- -1 enoyl glycerol Chemical compound 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-M (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC([O-])=O YUFFSWGQGVEMMI-JLNKQSITSA-M 0.000 claims description 2
- MYTYVDMLJOFYKT-UHFFFAOYSA-N 1,3-diethoxypropan-2-yl icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC(COCC)COCC MYTYVDMLJOFYKT-UHFFFAOYSA-N 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims description 2
- 208000009766 Blau syndrome Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010051606 Necrotising colitis Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 241001420836 Ophthalmitis Species 0.000 claims description 2
- 206010031149 Osteitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000010403 panophthalmitis Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 17
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 12
- 229960001243 orlistat Drugs 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 235000021323 fish oil Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000020958 lipid digestion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- CUXYLFPMQMFGPL-WJTNUVGISA-N Catalpic acid Chemical compound CCCC\C=C/C=C/C=C/CCCCCCCC(O)=O CUXYLFPMQMFGPL-WJTNUVGISA-N 0.000 description 2
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CUXYLFPMQMFGPL-UHFFFAOYSA-N alpha-Elaeostearinsaeure Natural products C(CCCCCCCC=CC=CC=CCCCC)(=O)O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- HXQHFNIKBKZGRP-URPRIDOGSA-N (5Z,9Z,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC\C=C/CCCC(O)=O HXQHFNIKBKZGRP-URPRIDOGSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- KBQNWRJBYWLXRH-UHFFFAOYSA-N CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC(COCCC)COCCC Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC(COCCC)COCCC KBQNWRJBYWLXRH-UHFFFAOYSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- 206010016260 Fatty acid deficiency Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010025477 Malabsorption conditions Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- HXQHFNIKBKZGRP-UHFFFAOYSA-N Ranuncelin-saeure-methylester Natural products CCCCCC=CCC=CCCC=CCCCC(O)=O HXQHFNIKBKZGRP-UHFFFAOYSA-N 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
Abstract
【選択図】なし
Description
1,3−ジアセチル−2−エイコサペンタエノイルグリセロール、
1,3−ジエチル−2−エイコサペンタエノイルグリセロール、
1,3−ジプロピル−2−エイコサペンタエノイルグリセロール、
sn−2モノエイコサペンタエノイルグリセロールのバニリン誘導体、
モノエイコサペンタエノイルグリセロールの他のアセタール誘導体、又は
それらの組み合わせ
からなる群から選択され得る。
Claims (15)
- sn−2モノアシグリセロール誘導体を含む組成物であって、sn−1位及びsn−3位は保護基でブロックされており、アシル基は抗炎症性を有する脂肪酸である、組成物。
- 抗炎症性を有する脂肪酸は、エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)、α−リノレン酸(ALA)、ステアリドン酸(SA)、γ−リノレン酸(GLA)、ジホモ−γ−リノレン酸(DGLA)、n−3ドコサペンタエン酸(DPA)、シアドン酸及びジュニペロン酸からなる群から選択される、請求項1に記載の組成物。
- 保護基は、アセチル基、エチル基、プロピル基、バニリン、又はアセタールを形成可能な他の分子からなる群から選択される、請求項1又は2に記載の組成物。
- sn−2モノアシルグリセロール誘導体は、1,3−ジアセチル−2−エイコサペンタエノイルグリセロール、1,3−ジエチル−2−エイコサペンタエノイルグリセロール、1,3−ジプロピル−2−エイコサペンタエノイルグリセロール、sn−2モノエイコサペンタエノイルグリセロールのバニリン誘導体、モノエイコサペンタエノイルグリセロールの他のアセタール誘導体、又はそれらの組み合わせからなる群から選択される、請求項1〜3のいずれか一項に記載の組成物。
- 食品、動物用食品、医薬組成物、栄養組成物、栄養補強食品、飲料、食品添加物又は薬剤からなる群から選択される、請求項1〜4のいずれか一項に記載の組成物。
- 0.5kcal/ml〜15kcal/mlのカロリー密度を有する、請求項1〜5のいずれか一項に記載の組成物。
- sn−2モノアシルグリセロール誘導体が組成物のエネルギーの約3%〜40%をもたらす、請求項1〜6のいずれか一項に記載の組成物。
- 異なるsn−2モノアシルグリセロール誘導体の組み合わせを含有し、例えば、n−3脂肪酸対n−6脂肪酸の比が約5:1〜約15:1(例えば、約8:1〜約10:1)である、請求項1〜7のいずれか一項に記載の組成物。
- 特に脂質消化不良又は脂質吸収不良の状態下で、抗炎症性を有する脂肪酸の送達に使用するための、請求項1〜8のいずれか一項に記載の組成物。
- 脂質消化不良又は脂質吸収不良の状態に罹患している対象に投与される、請求項1〜9のいずれか一項に記載の組成物。
- 脂質消化不良又は脂質吸収不良の状態は膵機能不全、胆汁塩欠乏、粘膜疾患及び/又は短腸によるものである、請求項9に記載の組成物。
- 炎症性障害の治療又は予防に使用するための、請求項1〜11のいずれか一項に記載の組成物。
- 炎症性障害は、急性炎症、例えば敗血症、及び慢性炎症、例えば、炎症性大腸炎、クローン病、潰瘍性大腸炎、壊死性腸炎、皮膚炎(例えば、紫外線又は化学物質誘発皮膚炎)、湿疹、敏感肌、乾癬、白斑、座瘡、炎症性腸症候群、肝炎、アルコール性肝硬変、アレルギー、アトピー、骨炎症、関節リウマチ、全身性エリテマトーデス、皮膚筋炎、甲状腺炎、I型糖尿病、セリアック病、ビールメル病、多発性硬化症、脳脊髄炎、眼炎、肥満に関連する炎症、加齢に関連する軽度の炎症、ブラウ症候群、アルツハイマー病、心血管疾患、アテローム性動脈硬化症、メタボリック症候群からなる群から選択される、請求項1〜12のいずれか一項に記載の組成物。
- 脂質消化不良又は脂質吸収不良の状態に関連する疾患の治療又は予防に使用するための、請求項1〜13のいずれか一項に記載の組成物。
- 早産児に投与される、請求項14に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10168420.7 | 2010-07-05 | ||
EP10168420.7A EP2409695B1 (en) | 2010-07-05 | 2010-07-05 | Sn-2-monoacylglycerols and lipid malabsorption |
PCT/EP2011/061265 WO2012004234A1 (en) | 2010-07-05 | 2011-07-05 | Sn-2-monoacylglycerols and lipid malabsorption |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013530999A true JP2013530999A (ja) | 2013-08-01 |
JP6157349B2 JP6157349B2 (ja) | 2017-07-05 |
Family
ID=42669828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013517348A Active JP6157349B2 (ja) | 2010-07-05 | 2011-07-05 | sn−2−モノアシルグリセロール及び脂質吸収不良 |
Country Status (8)
Country | Link |
---|---|
US (5) | US20130109753A1 (ja) |
EP (2) | EP2409695B1 (ja) |
JP (1) | JP6157349B2 (ja) |
CN (1) | CN103002889B (ja) |
DK (2) | DK2409695T3 (ja) |
ES (2) | ES2667011T3 (ja) |
TR (1) | TR201808471T4 (ja) |
WO (1) | WO2012004234A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016528279A (ja) * | 2013-08-19 | 2016-09-15 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 |
JP2016529322A (ja) * | 2013-09-03 | 2016-09-23 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分に含有するアトピー皮膚炎の予防または治療用組成物 |
JP2016532701A (ja) * | 2013-08-19 | 2016-10-20 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する関節リウマチの予防または治療用組成物 |
JP2016535036A (ja) * | 2013-10-28 | 2016-11-10 | ネステク ソシエテ アノニム | 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 |
JP2016535037A (ja) * | 2013-10-28 | 2016-11-10 | ネステク ソシエテ アノニム | 非機械的基礎を有する吸収不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2875458T3 (es) * | 2010-12-29 | 2021-11-10 | Abbott Lab | Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño |
EP2508180A1 (en) * | 2011-04-04 | 2012-10-10 | Nestec S.A. | Sn-1(3) Monoacylglycerides and lipid absorption |
US9825241B2 (en) | 2013-02-11 | 2017-11-21 | Philips Lighting Holding B.V. | Green emitting phosphors combined with broad band organic red emitters with a sharp near IR cut off |
BR112017007261A2 (pt) * | 2014-10-27 | 2017-12-19 | Nestec Sa | composições nutricionais compreendendo sn-1 (3) monoacilgliceróis para uso no tratamento da má absorção ou má digestão em bebês ou crianças pequenas |
WO2017003992A1 (en) | 2015-07-02 | 2017-01-05 | Stepan Company | Method for preparing 2-monoacylglycerides |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59190948A (ja) * | 1983-04-14 | 1984-10-29 | ルセル―ユクラフ | 新規なトリグリセリド、その製造法、食餌療法及び治療法への使用並びにそれを含む組成物 |
JPS6387988A (ja) * | 1986-10-01 | 1988-04-19 | Nisshin Oil Mills Ltd:The | 消化吸収性の良い油脂 |
JPH04316539A (ja) * | 1991-05-23 | 1992-11-06 | Roussel Uclaf | 新規なトリグリセリド、その製造法、食餌療法及び治療法への使用並びにそれを含む組成物 |
US20040025417A1 (en) * | 2001-12-19 | 2004-02-12 | Institut Francais Du Petrole | Diesel fuel compositions that contain glycerol acetal carbonates |
JP2005225863A (ja) * | 2004-01-16 | 2005-08-25 | Fuji Oil Co Ltd | リパーゼ阻害剤 |
JP2006528233A (ja) * | 2003-05-14 | 2006-12-14 | ビーティージー・インターナショナル・リミテッド | 神経変性状態の治療 |
JP2007502805A (ja) * | 2003-08-18 | 2007-02-15 | ビーティージー・インターナショナル・リミテッド | 神経変性状態の処置 |
JP2008531675A (ja) * | 2005-03-02 | 2008-08-14 | ビーティージー・インターナショナル・リミテッド | 必須多価不飽和脂肪酸の環式グリセリドを使用するサイトカイン調節物質 |
JP2009084230A (ja) * | 2007-10-01 | 2009-04-23 | Idemitsu Kosan Co Ltd | 炎症抑制剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
WO2005067913A1 (ja) * | 2004-01-16 | 2005-07-28 | Fuji Oil Company, Limited | リパーゼ阻害剤 |
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
-
2010
- 2010-07-05 ES ES10168420.7T patent/ES2667011T3/es active Active
- 2010-07-05 TR TR2018/08471T patent/TR201808471T4/tr unknown
- 2010-07-05 DK DK10168420.7T patent/DK2409695T3/en active
- 2010-07-05 EP EP10168420.7A patent/EP2409695B1/en active Active
-
2011
- 2011-07-05 WO PCT/EP2011/061265 patent/WO2012004234A1/en active Application Filing
- 2011-07-05 EP EP11729629.3A patent/EP2590644B1/en active Active
- 2011-07-05 ES ES11729629T patent/ES2769296T3/es active Active
- 2011-07-05 US US13/808,779 patent/US20130109753A1/en not_active Abandoned
- 2011-07-05 JP JP2013517348A patent/JP6157349B2/ja active Active
- 2011-07-05 DK DK11729629.3T patent/DK2590644T3/da active
- 2011-07-05 CN CN201180033290.4A patent/CN103002889B/zh active Active
-
2014
- 2014-01-24 US US14/163,163 patent/US9034917B2/en active Active
-
2015
- 2015-04-14 US US14/686,340 patent/US9522132B2/en active Active
-
2016
- 2016-11-10 US US15/348,334 patent/US9687462B2/en active Active
-
2017
- 2017-04-28 US US15/581,558 patent/US10039742B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59190948A (ja) * | 1983-04-14 | 1984-10-29 | ルセル―ユクラフ | 新規なトリグリセリド、その製造法、食餌療法及び治療法への使用並びにそれを含む組成物 |
JPS6387988A (ja) * | 1986-10-01 | 1988-04-19 | Nisshin Oil Mills Ltd:The | 消化吸収性の良い油脂 |
JPH04316539A (ja) * | 1991-05-23 | 1992-11-06 | Roussel Uclaf | 新規なトリグリセリド、その製造法、食餌療法及び治療法への使用並びにそれを含む組成物 |
US20040025417A1 (en) * | 2001-12-19 | 2004-02-12 | Institut Francais Du Petrole | Diesel fuel compositions that contain glycerol acetal carbonates |
JP2006528233A (ja) * | 2003-05-14 | 2006-12-14 | ビーティージー・インターナショナル・リミテッド | 神経変性状態の治療 |
JP2007502805A (ja) * | 2003-08-18 | 2007-02-15 | ビーティージー・インターナショナル・リミテッド | 神経変性状態の処置 |
JP2005225863A (ja) * | 2004-01-16 | 2005-08-25 | Fuji Oil Co Ltd | リパーゼ阻害剤 |
JP2008531675A (ja) * | 2005-03-02 | 2008-08-14 | ビーティージー・インターナショナル・リミテッド | 必須多価不飽和脂肪酸の環式グリセリドを使用するサイトカイン調節物質 |
JP2009084230A (ja) * | 2007-10-01 | 2009-04-23 | Idemitsu Kosan Co Ltd | 炎症抑制剤 |
Non-Patent Citations (8)
Title |
---|
AM. J. CLIN. NUTR., 1995, VOL.61, P.56-61, JPN6015023782, ISSN: 0003274049 * |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, VOL.6(4), P.345-348, JPN6015023780, ISSN: 0003274046 * |
GUILLON J: "FIRST TOTAL SYNTHESIS OF 1,3-DIACETYL- AND -DIBUTYROYL-2-OLEOYLGLYCEROL, 以下備考", PHARMACY AND PHARMACOLOGY COMMUNICATIONS, vol. V5 N5, JPN5013008074, 1 May 1999 (1999-05-01), GB, pages 311 - 313, ISSN: 0003545338 * |
PROCESS BIOCHEMISTRY, 2008, VOL.43, P.1033-1039, JPN6015023783, ISSN: 0003545339 * |
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1995, VOL.52, P.293-297, JPN6016009161, ISSN: 0003274048 * |
TETRAHEDRON, 2010/FEB, VOL.66, P.2728-2731, JPN6015023779, ISSN: 0003095359 * |
THE JOURNAL OF TRAUMA, 2010/1, VOL.68(1), P.62-68, JPN6016009159, ISSN: 0003274047 * |
改訂三版 油脂化学便覧, 1990, P.78-81, JPN6016040627, ISSN: 0003425600 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016528279A (ja) * | 2013-08-19 | 2016-09-15 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 |
JP2016532701A (ja) * | 2013-08-19 | 2016-10-20 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分として含有する関節リウマチの予防または治療用組成物 |
JP2016529322A (ja) * | 2013-09-03 | 2016-09-23 | エンジーケム ライフサイエンシーズ コーポレーションEnzychem Lifesciences Corporation | モノアセチルジアシルグリセロール化合物を有効成分に含有するアトピー皮膚炎の予防または治療用組成物 |
JP2016535036A (ja) * | 2013-10-28 | 2016-11-10 | ネステク ソシエテ アノニム | 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 |
JP2016535037A (ja) * | 2013-10-28 | 2016-11-10 | ネステク ソシエテ アノニム | 非機械的基礎を有する吸収不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 |
Also Published As
Publication number | Publication date |
---|---|
TR201808471T4 (tr) | 2018-07-23 |
US10039742B2 (en) | 2018-08-07 |
ES2769296T3 (es) | 2020-06-25 |
US20130109753A1 (en) | 2013-05-02 |
CN103002889A (zh) | 2013-03-27 |
US20170056362A1 (en) | 2017-03-02 |
WO2012004234A1 (en) | 2012-01-12 |
JP6157349B2 (ja) | 2017-07-05 |
US9034917B2 (en) | 2015-05-19 |
US20170296507A1 (en) | 2017-10-19 |
US20150224079A1 (en) | 2015-08-13 |
EP2590644B1 (en) | 2020-01-01 |
EP2409695A1 (en) | 2012-01-25 |
DK2590644T3 (da) | 2020-02-17 |
US9522132B2 (en) | 2016-12-20 |
US9687462B2 (en) | 2017-06-27 |
DK2409695T3 (en) | 2018-05-28 |
EP2409695B1 (en) | 2018-03-21 |
US20140142169A1 (en) | 2014-05-22 |
EP2590644A1 (en) | 2013-05-15 |
CN103002889B (zh) | 2017-03-29 |
ES2667011T3 (es) | 2018-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6157349B2 (ja) | sn−2−モノアシルグリセロール及び脂質吸収不良 | |
JP6170033B2 (ja) | sn−1(3)モノアシルグリセリド及び脂質吸収 | |
US20180133190A1 (en) | Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion | |
US20160263073A1 (en) | Monoacylglycerols for use in the treatment of malabsorption having a mechanical basis | |
US20160263072A1 (en) | Monoacylglycerols and fat-soluble nutrients for use in the treatment of malabsorption having a non-mechanical basis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160908 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170224 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170410 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170606 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6157349 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |